A CRISPR/Cas-Mediated Selection-free Knockin Strategy in Human Embryonic Stem Cells  by Zhu, Zengrong et al.
Stem Cell Reports
ResourceA CRISPR/Cas-Mediated Selection-free Knockin Strategy in Human
Embryonic Stem Cells
Zengrong Zhu,1,3 Nipun Verma,1,2,3 Federico Gonza´lez,1 Zhong-Dong Shi,1 and Danwei Huangfu1,*
1Developmental Biology Program, Sloan Kettering Institute, 1275 York Avenue, New York, NY 10065, USA
2Weill Graduate School ofMedical Sciences at Cornell University/The Rockefeller University/Sloan Kettering Institute Tri-InstitutionalM.D.-Ph.D. Program,
1300 York Avenue, New York, NY 10065, USA
3Co-first author
*Correspondence: huangfud@mskcc.org
http://dx.doi.org/10.1016/j.stemcr.2015.04.016
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYThe development of new gene-editing tools, in particular the CRISPR/Cas system, has greatly facilitated site-specific mutagenesis in hu-
man embryonic stem cells (hESCs), including the introduction or correction of patient-specificmutations for diseasemodeling. However,
integration of a reporter gene into an endogenous locus in hESCs still requires a lengthy and laborious two-step strategy that involves first
drug selection to identify correctly targeted clones and then excision of the drug-resistance cassette. Through the use of iCRISPR, an effi-
cient gene-editing platformwe recently developed, this study demonstrates a knockin strategywithout drug selection for both active and
silent genes in hESCs. Lineage-specific hESC reporter lines are useful for real-timemonitoring of cell-fate decisions and lineage tracing, as
well as enrichment of specific cell populations during hESC differentiation. Thus, this selection-free knockin strategy is expected to
greatly facilitate the use of hESCs for developmental studies, disease modeling, and cell-replacement therapy.INTRODUCTION
Human embryonic stem cells (hESCs) are capable of unlim-
ited self-renewal in culture while maintaining the potential
to differentiate into any cell type present in the human
body and thus provide researchers great opportunities for
human developmental studies, disease modeling, and cell-
replacement therapies (Zhu and Huangfu, 2013). All these
applications benefit from lineage-specific knockin reporters
that allow real-time observation of gene-expression dy-
namics, cell-lineage tracing, and isolation of a specific
cell population of interest from a heterogeneous differenti-
ation culture for downstream analysis. However, creating
knockin alleles in hESCs is usually a lengthy and technically
challenging process. Because of the low efficiency of homol-
ogous recombination, the donor vector needs to contain a
drug-resistance gene for enrichment of cellswith the correct
integration. Due to the concern that the insertion of a drug-
resistance cassette may interfere with the expression of the
reporter gene or neighboring genes, it is usually necessary to
remove the drug-resistance cassette through a second elec-
troporation step followed by isolation of clonal lines and
further characterization (Davis et al., 2008). Thus, substan-
tial time and effort is needed to generate a knockin reporter
hESC line through this two-step procedure.
The development of engineered ‘‘genomic scissors’’ that
introduce site-specific DNA double-strand breaks (DSBs),
including zinc finger nucleases (ZFNs), transcription acti-
vator-like effector nucleases (TALENs), and more recently
the clustered regularly interspaced short palindromic repeat
(CRISPR)/CRISPR-associated (Cas) system, has greatly facili-Stem Ctated gene targeting in hESCs (Kim and Kim, 2014). Repair
of a DSB by non-homologous end joining (NHEJ) often re-
sults in insertion and/or deletions (Indels) that can be
used to knock out a target gene in hESCs (Ding et al.,
2013a, b; Gonza´lez et al., 2014). Alternatively, homology-
directed repair (HDR) can be employed to efficiently incor-
porate exogenous sequences such as a fluorescent reporter
into a specific genomic locus in hESCs (Hockemeyer et al.,
2009, 2011; Hou et al., 2013; Merkert et al., 2014). Despite
the significant improvement, a drug-resistance cassette is
still required for generating knockin reporters of genes
that are not expressed in undifferentiated hESCs.
To overcome these limitations, we made use of the
CRISPR/Cas system, in which the CRISPR RNA (crRNA)
and trans-activating crRNA (tracrRNA) duplex or a single
chimeric guide RNA (gRNA) recognizes a 20-nucleotide
(nt) DNA sequence upstream of the 50-NGG-30 protospacer
adjacent motif (PAM) and directs the DNA endonuclease
Cas9 for site-specific cleavage (Cong et al., 2013; Jinek
et al., 2012;Mali et al., 2013a). Based on this, we have devel-
oped an efficient genome-editing platform in hESCs, which
wenamed iCRISPR (Gonza´lez et al., 2014). Through TALEN-
mediatedgene targeting in theAAVS1 locus,wehave created
hESC lines (referred to as iCas9 hESCs) that allow robust,
doxycycline-inducible expression of Cas9. By transfecting
iCas9 hESCs with gRNAs, the iCRISPR system enables effi-
cient NHEJ-mediated gene disruption as well as HDR-medi-
ated precise nucleotide modifications in the presence of
short single-stranded DNA (ssDNA) donors (100 nt).
We reasoned that the iCRISPR system would also facili-
tate the generation of knockin reporter alleles using longerell Reports j Vol. 4 j 1103–1111 j June 9, 2015 j ª2015 The Authors 1103
double-stranded (dsDNA) donors and may further enable
the identification of correctly targeted hESC lines without
drug selection. Thus, this work explores the utility of
iCRISPR for targeting fluorescent reporters into two endog-
enous loci, OCT4 (POU5F1) and PDX1, and demonstrates
the generation of knockin hESC lines without drug selec-
tion for both expressed and silent genes. Further character-
ization confirmed the creation of multiple hESC reporter
lines with no undesired mutations in the targeted loci or
any potential off-target sites analyzed, supporting the
broad application of this approach for efficient generation
of knockin alleles in hESCs.RESULTS
CRISPR/Cas-Mediated Targeting of the OCT4 Locus
We first evaluated the efficiency of the CRISPR/Cas system
for making knockin reporter alleles by targeting the OCT4
locus using drug selection. HUES8 hESCs were co-electro-
porated with two plasmids: one expressing Cas9 and a
crRNA/tracrRNA duplex targeting OCT4 and the other
containing the fluorescent reporter and a drug-resistance
cassette as the HDR template (Figures 1A, S1A, and S1B).
We used a donor plasmid, 2A-eGFP-PGK-Puro (Hocke-
meyer et al., 2011), in which the last OCT4 coding codon
is fused in frame with a 2A sequence followed by eGFP
(2A-eGFP) and a loxP-flanked (floxed) puromycin-resis-
tance gene expressed from the constitutive PGK promoter
(PGK-Puro) (Figure 1A). This strategyminimizes any poten-
tial impact on the endogenous protein and is applicable to
targeting both silent and expressed genes. PCR and South-
ern blot analysis identified eight correctly targeted clones
without random transgene integration from a total of 288
puromycin-resistant clones screened (Figures 1B and
S1C). The targeting efficiency (2.8%) was comparable to
the efficiencies observed with TALENs and ZFNs using
similar targeting strategies (Hockemeyer et al., 2009, 2011).
Despite correct targeting, we failed to detect eGFP expres-
sion in any of the targeted lines. This is likely caused by the
presence of the drug-resistance cassette as observed for
other genes (Davis et al., 2008). Indeed, after Cre-mediated
excision of the PGK-Puro cassette, all resulting OCT4-eGFP
lines showed proper co-expression of eGFP with pluripo-
tency markers OCT4, SOX2, and NANOG (Figures 1C,
1D, and S1D). These results highlight the necessity of
removing the drug-resistance cassette for proper reporter
gene expression.Selection-free Targeting of the OCT4 Locus Using a
Mini-vector Donor
To further explore the possibility of making knockin re-
porter alleles without drug selection, we designed a ‘‘mini-1104 Stem Cell Reports j Vol. 4 j 1103–1111 j June 9, 2015 j ª2015 The Autvector’’ donor plasmid, 2A-mOrange, which is similar
to 2A-eGFP-PGK-Puro except that there is no PGK-Puro
cassette and eGFP was replaced by mOrange (Figure 2A).
We also replaced the crRNA/tracrRNA duplex cr1-dp with
the single gRNA cr1 targeting the same sequence (Figures
2A and S2A), as the chimeric versionworksmore efficiently
than theoriginal duplex design (Hsu et al., 2013; Jinek et al.,
2012). Similar to the experiment with the 2A-eGFP-PGK-
Puro donor, we co-electroporated HUES8 hESCs with a
plasmid expressing Cas9/gRNA and the new 2A-mOrange
mini-vector (Figure 2A). In contrast to the absence of
fluorescence after integration of the 2A-eGFP-PGK-Puro
cassette, integration of the 2A-mOrange cassette resulted
in mOrange expression in 0.001% of cells as detected by
fluorescence-activated cell sorting (FACS) (Figure S2B).
One may enrich mOrange-expressing cells for establishing
OCT4 reporter lines. However, this low efficiency is imprac-
tical for genes not expressed in undifferentiated hESCs, as
one has to rely on randomly picking individual colonies
to establish clonal lines.
Our recent study shows that the iCRISPR platform en-
ables efficient gene editing using short ssDNA HDR
templates (Gonza´lez et al., 2014), prompting us to further
optimize the iCRISPR platform for HDR using longer circu-
lar dsDNA donor vectors. After optimizing transfection
conditions, we co-transfected doxycycline-treated HUES8
iCas9 cells twice in 2 days with the OCT4 cr1 gRNA and
the 2A-mOrange mini-vector using Lipofectamine 3000
(Figures S2D and S3). FACS analysis identified 0.4%
mOrange-expressing cells (Figure 2B), >100-fold greater
than results from our electroporation experiments (Figures
S2B and S2C). Similar results were observed in experiments
using iCas9 cells generated fromMEL-1 hESCs (Figure S2E),
supporting the general utility of this new approach in
diverse human pluripotent stem cell (hPSC) backgrounds.
The much-improved efficiencies can be partially attributed
to the integration of Cas9 in the genome as an5- to 6-fold
increase of mOrange+ cells was observed compared to the
control condition where iCas9 hESCs (not treated with
doxycycline) were transfected with Cas9/gRNA and the
donor vector using Lipofectamine 3000 (Figure 2C). The
use of Lipofectamine transfection also substantially
increased the targeting efficiency compared to the electro-
poration method (Figures S2B and S2C). There may be
other ways to improve the transfection efficiency (e.g.,
through nucleofection) to achieve similar results with or
without the use of iCas9 hESCs (Byrne et al., 2015).
We picked ten colonies from individual FACS-isolated
mOrange+ cells and identified six correctly targeted clones
by PCR and Southern blot analysis (Figures 2B, 2D, and
S2F). All six lines co-expressed mOrange with pluripotency
markers such as OCT4, SOX2, and NANOG and displayed
normal hESC morphology (Figure S2G). We furtherhors
AB
C
D
Si
de
 S
ca
tte
r
loxP
loxP
Figure 1. CRISPR/Cas-Mediated Targeting of the OCT4 Locus through Drug Selection
(A) Schematics of the targeting strategy. In the presence of the donor plasmid, HDR results in the replacement of the OCT4 stop codon with
2A-eGFP-PGK-Puro. The PCR primers (F + GFP-R) used for genotyping are indicated with red arrowheads. OCT4 cr1-dp (the duplex version)
targets a 30-nt sequence (indicated with a green line) upstream of the PAM sequence (indicated with a purple line). In all targeting
schematics here and after, boxes are exons, filled blue boxes indicate the coding sequence (CDS), connecting lines are introns, the stop
codon (TGA) is labeled in red, HL and HR indicate left and right homology arms, and the Southern blot external and internal probes are
indicated with red bars.
(B) Southern blot analysis using the external probe (WT: 4,173 bp; GFP+Puro: 6,835 bp) and the internal puromycin probe (GFP+Puro:
2,415 bp) identified eight correctly targeted clones, which are labeled in red. WT, wild-type allele; GFP+Puro, correctly targeted allele with
puromycin-selection cassette.
(C) Three of the correctly targeted clones (nos. 1, 4, and 7) were electroporated with Cre recombinase. Four days after electroporation,
eGFP+ cells were isolated using FACS.
(D) For each clone (nos. 1, 4, and 7) electroporated with CRE recombinase, two GFP+ clones were picked (e.g., C1.1 and C1.2 for clones
derived from no. 1), and Southern blot analysis using the external probe (WT: 4,173 bp; GFP+Puro: 6,835 bp; GFP only: 5,015 bp) and the
internal puromycin probe (GFP+Puro: 2,415 bp) showed correct removal of the puromycin-selection cassette. A clone (C1) prior to Cre
electroporation was used as the Pre-Cre control. GFP+Puro, targeted allele prior to Cre-mediated excision of the PGK-Puro cassette; GFP
only, targeted allele after Cre-mediated excision.examined the OCT4-mOrange hESC reporter lines along
with theOCT4-eGFP lines for reporter gene expression after
differentiation. After 3 days of treatment with BMP4 and
SB431542, a TGFb inhibitor (Hou et al., 2013), hESCs
exhibited a differentiated morphology, and eGFP and
mOrange expression were downregulated in the respective
OCT4-eGFP and OCT4-mOrange hESC reporter lines withStem Cconcomitant loss of endogenous OCT4 expression as deter-
mined by immunostaining and FACS analysis (Figures 3A
and 3B). Thus, the OCT4-eGFP and OCT4-mOrange re-
porters faithfully reflect endogenous gene expression dur-
ing the maintenance and differentiation of hESCs.
We next investigated whether the relatively high target-
ing efficiency was achieved at the expense of undesirableell Reports j Vol. 4 j 1103–1111 j June 9, 2015 j ª2015 The Authors 1105
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Figure 2. Targeting the OCT4 Locus without Drug Selection
(A) Schematics of the targeting strategy without drug selection. In the presence of the donor plasmid, HDR results in the replacement of
the stop codon with 2A-mOrange. OCT4 cr1 targets a 20-nt sequence upstream of the PAM sequence. The PCR primers (F + mOr-R) used for
genotyping are indicated with red arrowheads.
(B) FACS enrichment for OCT4-mOrange+ cells after transfection of the OCT4-mOrange donor plasmid and the OCT4-targeting gRNA into
HUES8 iCas9 cells treated with doxycycline.
(C) FACS analysis for OCT4-mOrange fluorescence in doxycycline-treated HUES8 iCas9 cells co-transfected with the OCT4-mOrange donor
plasmid and the OCT4-targeting gRNA, compared to HUES8 iCas9 cells (not treated with doxycycline) co-transfected with the Cas9/gRNA
and the donor plasmids using Lipofectamine 3000.
(D) Ten colonies were randomly picked from individual FACS-enriched mOrange+ cells. Southern blot analysis using the external probe (WT:
4,173 bp; mOrange: 4,963 bp) and the internal mOrange probe (mOrange: 4,963 bp) identified six correctly targeted clones, which are
labeled in red. mOrange: correctly targeted allele.mutations at the OCT4 locus or any off-target sites. All
eight OCT4-eGFP and six OCT4-mOrange lines examined
showed the expected sequence at the junction between
the endogenous OCT4 sequence and the inserted seq-
uence. This is reassuring, as we made sure that the donor
template did not contain the CRISPR target sequence to
prevent undesired mutagenesis after reporter gene integra-
tion. However, Indel mutations were detected in the non-
targeted allele in two of the six OCT4-mOrange reporter
lines examined (Figure 3C). These findings underscore
the necessity of thorough sequence analysis for elimi-
nating clones with undesired mutations in the non-
targeted allele, a point not widely recognized with the
CRISPR/Cas-mediated targeting strategy. We also
sequenced seven predicted off-target sites based on the
12-bp seed sequence important for target recognition1106 Stem Cell Reports j Vol. 4 j 1103–1111 j June 9, 2015 j ª2015 The Aut(Jiang et al., 2013; Jinek et al., 2012). Examination of six
OCT4-mOrange and eightOCT4-eGFP lines revealed nomu-
tations except that three OCT4-eGFP lines carried muta-
tions at the POU5F1P4 locus, which shares the same
20-nt target sequence with the intended target (Table S1).
Targeting the PDX1 Locus Using a Mini-vector Donor
without Drug Selection
We further investigated whether this selection-free
approach also applied to genes not expressed in undifferen-
tiated hESCs. We chose to target PDX1, which encodes a
transcription factor not expressed in undifferentiated
hESCs but in pancreatic progenitors and their differenti-
ated progeny such as pancreatic b cells. The ability to
monitor PDX1 expression during in vitro differentiation
and to enrich PDX1+ pancreatic progenitor cells or b cellshors
CA
B
Figure 3. Characterization of OCT4 Reporter Lines
(A) OCT4-eGFP and OCT4-mOrange hESCs were treated with SB431542 and BMP4 to initiate differentiation. Three days after this treatment,
the cells displayed concomitant loss of OCT4 protein expression with GFP or mOrange by immunostaining. An RFP antibody was used to
detect mOrange expression, whereas the GFP expression was detected directly. The scale bar represents 100 mm.
(B) Three days after SB431542 and BMP4 treatment, flow cytometry analysis showed a loss of GFP and mOrange, verifying that OCT4-eGFP
and OCT4-mOrange reporter hESCs can respond to differentiation cues and that GFP and mOrange accurately reflects OCT4 expression.
(C) Sequencing results of the non-targeted allele and at the junction of correctly targeted allele in OCT4-eGFP and OCT4-mOrange reporter
lines.would be valuable for studies of pancreatic development
and the use of hESCs for b cell replacement therapies.
We designed two gRNAs (PDX1 cr1 and cr2) to target
DNA sequences in proximity to the PDX1 stop codon and
used a PDX1-eGFP mini-vector donor for integration of
the eGFP reporter into the PDX1 locus (Figures 4A andStem CS4A). Correct targeting should enable expression of eGFP
from the endogenous PDX1 locus with minimal impact
on PDX1 protein expression or function. Following estab-
lishment of clonal lines (Figure 4B), PCR and Southern
blot analysis identified three correctly targeted clones
without random integration: two clones with eGFPell Reports j Vol. 4 j 1103–1111 j June 9, 2015 j ª2015 The Authors 1107
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Figure 4. Generation of PDX1-eGFP Reporter Lines without Drug Selection
(A) PDX1 cr1 and cr2 were designed to target sequences in proximity to the PDX1 stop codon. In the presence of the eGFP donor plasmid,
HDR resulted in the replacement of the stop codon with 2A-eGFP. PCR primers (F + R) used for genotyping are indicated with red ar-
rowheads.
(B) Timeline for the generation of PDX1-eGFP hESC lines using the iCRISPR platform. DOX, doxycycline.
(C) PCR genotyping of 12 clones, identified from the PCR screen in Figure S4B, that showed the correct PCR product for the targeted allele
(GFP: 1,746 bp).
(D) Southern blot analysis using the external probe and internal probe (WT: 3,845 bp; GFP: 4,632 bp) identified three correctly targeted
lines. Lines without random integrations and carrying mono-allelic eGFP insertion are labeled in red, and the clone with a bi-allelic eGFP
insertion is labeled in green.
(E) Immunofluorescence staining displayed co-expression of GFP and PDX1 in pancreatic progenitors differentiated from PDX1-eGFP hESCs.
The scale bar represents 100 mm.
(F) Sanger sequencing of non-targeted and targeted PDX1 alleles showed correct targeting of the PDX1 locus with no undesired mutations.integration in one PDX1 allele and one clone with biallelic
integration (Figures 4C, 4D, and S4B). All three PDX1-eGFP
reporter lines displayed normal hESC morphology and ex-
pressed pluripotencymarkersOCT4, NANOG, and SOX2 as
determined by immunofluorescence staining (Figure S4C).
After differentiation into pancreatic progenitors, co-expres-
sion of GFP and PDX1 was observed, demonstrating faith-
ful reporter activity (Figure 4E). Thus, we successfully
generated multiple faithful knockin reporter lines for1108 Stem Cell Reports j Vol. 4 j 1103–1111 j June 9, 2015 j ª2015 The AutPDX1, a gene with a lineage-restricted expression pattern
in differentiated hESCs.
We further examined the PDX1 reporter lines for poten-
tial undesired mutations similar to analysis performed on
the OCT4 reporter lines. We found the expected sequences
in both the targeted and non-targeted PDX1 allele in all
clones (Figure 4F) except for one (no. 3) with a 24-bp dele-
tion in the non-targeted allele. Recent studies suggest that
CRISPR/Cas9 tolerates mismatches between CRISPR andhors
target DNA at different positions in a sequence-dependent
manner, influenced by the number, position, and distribu-
tion of mismatches (Hsu et al., 2013; Tan et al., 2015). Us-
ing a prediction program developed by Feng Zhang’s group
(http://crispr.mit.edu), we sequenced 20 most likely off-
target sites (ten each predicted for PDX1 cr1 and cr2) and
detected no mutations (Table S1).DISCUSSION
Here, we demonstrate the generation of hESC reporter
lines without the use of drug selection for both active
and silent genes through the use of the iCRISPR system.
Selection-free gene targeting eliminates the need for
removal of drug-resistance cassette after identification of
correctly targeted clones, and mini-vector donors with
short homology arms (500–1,000 bp each) are conve-
nient to make. Thus, this method significantly reduces
the time and effort required for establishing hESC reporter
lines. Additionally, conventional gene-targeting strategies
typically use the Cre-loxP strategy to remove drug-resis-
tance cassettes, which leaves behind a 34-bp loxP ‘‘scar’’
in the endogenous locus. Although not an issue in most
cases, this residual sequence could interfere with the
expression of the targeted gene in some situations (Meier
et al., 2010). In comparison, our strategy eliminates the
need for the selection cassette and thereby minimizes
the alteration of the endogenous locus. Although we
focused on creating promoter-fusion reporters, the same
knockin approach can be readily applied to making pro-
tein-fusion reporters for visualizing protein subcellular
localization, precisely deleting or replacing specific
genomic sequences, and introducing or correcting dis-
ease-associated mutations.
Previously, we and others have failed to target the PDX1
locus using traditional targeting approaches (Z.Z. andD.H.,
data not shown; E. Stanley, personal communication), yet
the absolute targeting efficiencies using the selection-free
method were comparable between the PDX1 and OCT4
loci. It is known that gene-targeting efficiencies can vary
significantly depending on the target locus, though the
exact reason is unclear. Traditional gene targeting relies
on drug selection; thus, the relative targeting efficiencies af-
ter drug selection depend, at least in part, on the expression
of the drug-resistance gene from the targeted locus. Because
the expression of drug-resistance gene may differ signifi-
cantly between expressed and silent loci, the relative target-
ing efficiency after drug selection for a lineage-specific gene
may appear much lower compared with a pluripotency
gene. For certain loci, the drug-resistance gene may be ex-
pressed at such low levels that hinder the identification
of a correctly targeted clone using the drug-selectionStem Cmethod (Rostovskaya et al., 2012). Because our targeting
approach obviates drug selection, it may overcome such
bias and facilitate the generation of reporter alleles for
genes that were previously difficult to target. One may
further use this ability to measure absolute targeting fre-
quencies to compare HDR efficiencies across different
genomic contexts.
There have been concerns about potential off-target
mutagenesis with the CRISPR/Cas system (Cho et al.,
2014; Fu et al., 2013; Hsu et al., 2013; Mali et al., 2013b;
Pattanayak et al., 2013). Our analysis so far did not reveal
any off-target mutations at sites without perfect comple-
mentarity with the CRISPR target sequence. However, we
cannot exclude the possibility of off-target mutations else-
where in the genome, and a thorough analysis may be
necessary before the reporter lines are used in future
studies. The CRISPR/Cas system is continuously improved
with the development of better algorithms for CRISPR
design and off-target prediction. It is reassuring that a
recent high-coverage whole-genome sequencing study
failed to detect significant incidence of off-target muta-
tions in CRISPR-targeted hPSC lines (Veres et al., 2014).
On the other hand, we noticed that some correctly tar-
geted clones carried mutations in the non-targeted allele,
though the targeting efficiency is sufficiently high that
one could simply discard the minority of clones carrying
mutations. One may also target intronic regions with
low-sequence conservations to further mitigate any con-
cerns associated with Indel mutations in the non-targeted
allele.
Our selection-free targeting approach enables rapid gen-
eration of knockin reporter lines, though it also requires
either using established iCas9 cells or creating new iCas9
lines in a desired hPSC background. The upfront effort for
generating iCas9 cells is relatively small due to the efficient
TALEN-mediated AAVS1-targeting approach, and it is
possible to establish an iCas9 line in about 1 month (Gon-
za´lez et al., 2014; Zhu et al., 2014). Once an iCas9 line is
established, it can be used for making different types of re-
porters. Our previous study has shown that Cas9 activity is
tightly regulated by doxycycline treatment, and estab-
lished iCas9 lines exhibit no apparent chromosomal aber-
rations or defects in the maintenance of the pluripotent
state (Gonza´lez et al., 2014). A recent study also observed
no adverse effects in constitutive Cas9-expressing mice
(Platt et al., 2014). An additional benefit of using iCas9
hPSCs for making reporter lines is that the cells can be
conveniently used for a variety of downstream genetic
studies using gene-editing approaches we already estab-
lished (Gonza´lez et al., 2014). Thus, we expect this selec-
tion-free knockin strategy to further facilitate the use of
hESCs for developmental studies, disease modeling, and
cell-replacement therapy.ell Reports j Vol. 4 j 1103–1111 j June 9, 2015 j ª2015 The Authors 1109
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